# Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia

> **NCT03823365** · PHASE1 · UNKNOWN · sponsor: **A.O. Ospedale Papa Giovanni XXIII** · enrollment: 19 (actual)

## Conditions studied

- Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** Blinatumomab Expanded T-cells (BET)

## Key facts

- **NCT ID:** NCT03823365
- **Lead sponsor:** A.O. Ospedale Papa Giovanni XXIII
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-17
- **Primary completion:** 2021-11-11
- **Final completion:** 2022-11
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2021-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03823365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03823365, "Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03823365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*